Abstract Background: Atrial fibrillation (AFib) is highly prevalent in patients with clinically significant tricuspid regurgitation (TR), yet its prognostic relevance after tricuspid transcatheter edge-to-edge repair (T-TEER) remains controversial. We evaluated the prognostic impact of AFib in patients undergoing T-TEER for symptomatic secondary TR. Methods: In this sub-analysis of the retrospective, multicenter EuroTR Registry (NCT06307262), patients undergoing T-TEER for symptomatic relevant secondary TR were stratified by AFib status. Patients with primary or mixed TR etiology, concomitant mitral TEER, or missing baseline AFib data were excluded. The primary endpoint was the composite of all-cause death and heart failure hospitalization (HFH) at 2 years. Results: Among 2044 patients undergoing isolated T‑TEER, AFib was present in 92% and associated with more advanced symptoms and greater TR severity, with no differences in residual TR and post-procedural NYHA class. Across a median 526‑day follow‑up, AFib correlated with a lower risk of all‑cause death and HFH (HR 0.68; 95% CI 0.47-0.98; p=0.04). Prognosis varied by TR subtype: patients with A‑STR and AFib showed the most favorable outcomes, whereas V‑STR and non‑AFib patients had comparably higher event rates. The RVESA/EROA ratio independently predicted adverse outcomes (HR: 1.23; 95% CI: 1.11–1.37; p<0.001). Conclusions: AFib was associated with more advanced TR yet lower event risk after T‑TEER, particularly in A‑STR. In contrast, V‑STR and non‑AFib patients showed similarly worse outcomes. The RVESA/EROA ratio emerged as an independent marker of adverse prognosis.
Abstract Background: Atrial fibrillation (AFib) is highly prevalent in patients with clinically significant tricuspid regurgitation (TR), yet its prognostic relevance after tricuspid transcatheter edge-to-edge repair (T-TEER) remains controversial. We evaluated the prognostic impact of AFib in patients undergoing T-TEER for symptomatic secondary TR. Methods: In this sub-analysis of the retrospective, multicenter EuroTR Registry (NCT06307262), patients undergoing T-TEER for symptomatic relevant secondary TR were stratified by AFib status. Patients with primary or mixed TR etiology, concomitant mitral TEER, or missing baseline AFib data were excluded. The primary endpoint was the composite of all-cause death and heart failure hospitalization (HFH) at 2 years. Results: Among 2044 patients undergoing isolated T‑TEER, AFib was present in 92% and associated with more advanced symptoms and greater TR severity, with no differences in residual TR and post-procedural NYHA class. Across a median 526‑day follow‑up, AFib correlated with a lower risk of all‑cause death and HFH (HR 0.68; 95% CI 0.47-0.98; p=0.04). Prognosis varied by TR subtype: patients with A‑STR and AFib showed the most favorable outcomes, whereas V‑STR and non‑AFib patients had comparably higher event rates. The RVESA/EROA ratio independently predicted adverse outcomes (HR: 1.23; 95% CI: 1.11–1.37; p<0.001). Conclusions: AFib was associated with more advanced TR yet lower event risk after T‑TEER, particularly in A‑STR. In contrast, V‑STR and non‑AFib patients showed similarly worse outcomes. The RVESA/EROA ratio emerged as an independent marker of adverse prognosis.
Atrial Fibrillation and Clinical Outcomes After Tricuspid Transcatheter Edge-to-Edge Repair in functional tricuspid regurgitation: The EuroTR Registry
CAPOMOLLA, ANTONELLA
2024/2025
Abstract
Abstract Background: Atrial fibrillation (AFib) is highly prevalent in patients with clinically significant tricuspid regurgitation (TR), yet its prognostic relevance after tricuspid transcatheter edge-to-edge repair (T-TEER) remains controversial. We evaluated the prognostic impact of AFib in patients undergoing T-TEER for symptomatic secondary TR. Methods: In this sub-analysis of the retrospective, multicenter EuroTR Registry (NCT06307262), patients undergoing T-TEER for symptomatic relevant secondary TR were stratified by AFib status. Patients with primary or mixed TR etiology, concomitant mitral TEER, or missing baseline AFib data were excluded. The primary endpoint was the composite of all-cause death and heart failure hospitalization (HFH) at 2 years. Results: Among 2044 patients undergoing isolated T‑TEER, AFib was present in 92% and associated with more advanced symptoms and greater TR severity, with no differences in residual TR and post-procedural NYHA class. Across a median 526‑day follow‑up, AFib correlated with a lower risk of all‑cause death and HFH (HR 0.68; 95% CI 0.47-0.98; p=0.04). Prognosis varied by TR subtype: patients with A‑STR and AFib showed the most favorable outcomes, whereas V‑STR and non‑AFib patients had comparably higher event rates. The RVESA/EROA ratio independently predicted adverse outcomes (HR: 1.23; 95% CI: 1.11–1.37; p<0.001). Conclusions: AFib was associated with more advanced TR yet lower event risk after T‑TEER, particularly in A‑STR. In contrast, V‑STR and non‑AFib patients showed similarly worse outcomes. The RVESA/EROA ratio emerged as an independent marker of adverse prognosis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tesi_definitiva_AC.pdf
Accesso riservato
Dimensione
1.46 MB
Formato
Adobe PDF
|
1.46 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/120693